Physician profile
James Lettera
NPI 1700825593
$23,173.68
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $4,066 · 2021: $8,911 · 2022: $8,968 · 2023: $166 · 2024: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $500 · Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $500.00 |
| Food and Beverage | $194.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $19,354.98 | 2019-2023 | Corbel |
| Nuvasive, INC. | $2,036.98 | 2019-2021 | |
| Ethicon INC. | $720.00 | 2022 | |
| 4web, INC. | $500.00 | 2024 | Spine Truss System |
| Medtronic, INC. | $167.05 | 2023-2024 | Signia, Endo Gia Ultra |
| Lilly USA, LLC | $88.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $79.79 | 2019-2020 | |
| Amgen INC. | $60.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.77 | 2019 | |
| Biodelivery Sciences International, INC. | $31.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.46 | 2019 | |
| Merck Sharp & Dohme LLC | $14.49 | 2019 | |
| Avanos Medical | $13.02 | 2019 | |
| Medtronic Vascular, INC. | $12.10 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $10.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lettera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.